ACE and hydrops fetalis: Angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, and β-blockers, all known to increase survival in HF, have been shown to improve HRV parameters, such as SDNN, rMSSD, and pNN50 in patients with HF [70-76].